Graham Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Graham Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.5K	Buy	+47,920	New	+$91.2K	﹤0.01%	1168
2026 Q1	–	Sell	-191,416	Closed	-$343K	–	1404
2025 Q4	$343K	Buy	191,416 +34,483	+22%	+$75.5K	0.01%	797
2025 Q3	$286K	Sell	156,933 -308,932	-66%	-$499K	﹤0.01%	886
2025 Q2	$342K	Sell	465,865 -696,634	-60%	-$528K	0.01%	948
2025 Q1	$1.16M	Buy	1,162,499 +1,095,830	+1,644%	+$1.88M	0.02%	501
2024 Q4	$707K	Buy	+66,669	New	+$799K	0.01%	600

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Graham Capital Management's NMRA Position: Q2 2026 in Review

Graham Capital Management opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 47,920 shares worth $81.5K. The stake represents ﹤0.01% of the portfolio and ranks #1168 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in NMRA as recently as Q4 2025.

Graham Capital Management first reported a position in NMRA in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.16M in Q1 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Graham Capital Management held 47,920 shares of Neumora Therapeutics worth $81.5K as of Q2 2026.
Neumora Therapeutics was a new Graham Capital Management position in Q2 2026.
Neumora Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1168 holding.
Graham Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 6 quarters since.
Graham Capital Management's Neumora Therapeutics position peaked at $1.16M in Q1 2025.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.